BlossomHill Therapeutics (NASDAQ:BLSM) Shares Gap Up – Here’s Why

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) shares gapped up prior to trading on Thursday . The stock had previously closed at $19.38, but opened at $20.31. BlossomHill Therapeutics shares last traded at $20.05, with a volume of 15,940 shares trading hands.

Key Headlines Impacting BlossomHill Therapeutics

Here are the key news stories impacting BlossomHill Therapeutics this week:

• Positive Sentiment: Leerink Partners initiated coverage with an Outperform rating and a $36 price target, while HC Wainwright began coverage with a Buy rating and a $35 target. These targets imply substantial potential upside and provide new institutional validation for BlossomHill’s development strategy. BlossomHill Therapeutics analyst coverage
• Positive Sentiment: Guggenheim also initiated coverage with a Buy rating and a $30 price target, adding to the consensus bullish view. Lifesci Capital separately began coverage with an Outperform rating and a $32 target. Guggenheim initiates coverage
• Positive Sentiment: HC Wainwright projects that quarterly losses will narrow from $0.92 per share in the third quarter of 2026 to $0.69 per share by the third quarter of 2027. Its $35 price target and Buy rating reinforce the optimistic outlook. HC Wainwright earnings estimates
• Positive Sentiment: BlossomHill announced upcoming presentations at the RAS-Targeted Drug Development Summit and the H.C. Wainwright Global Investment Conference. The events may increase visibility for its cancer-focused small-molecule programs and create opportunities for investor engagement. BlossomHill conference presentation announcement
• Neutral Sentiment: Lifesci Capital and JPMorgan Chase also initiated coverage, expanding analyst attention around BLSM, although the supplied reports did not provide their ratings or price targets.
• Negative Sentiment: BlossomHill remains forecast to report losses, including estimated fiscal 2026 EPS of negative $3.71 and fiscal 2027 EPS of negative $2.99. Continued losses and the need to fund clinical development remain risks despite the expected improvement in earnings.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Guggenheim began coverage on BlossomHill Therapeutics in a research note on Tuesday. They set a “buy” rating and a $30.00 price target for the company. Wall Street Zen upgraded BlossomHill Therapeutics to a “hold” rating in a research note on Saturday, August 15th. Leerink Partners started coverage on shares of BlossomHill Therapeutics in a report on Tuesday. They set an “outperform” rating and a $36.00 price objective on the stock. HC Wainwright began coverage on shares of BlossomHill Therapeutics in a research report on Tuesday. They set a “buy” rating and a $35.00 target price for the company. Finally, Lifesci Capital initiated coverage on shares of BlossomHill Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $32.00 target price for the company. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat, BlossomHill Therapeutics presently has a consensus rating of “Buy” and an average price target of $32.20.

BlossomHill Therapeutics Price Performance

Insider Transactions at BlossomHill Therapeutics

In related news, Director Orbimed Advisors Llc purchased 625,000 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was purchased at an average cost of $16.00 per share, with a total value of $10,000,000.00. Following the completion of the acquisition, the director directly owned 2,714,279 shares of the company’s stock, valued at approximately $43,428,464. The trade was a 29.91% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director John P. Schmid purchased 6,000 shares of BlossomHill Therapeutics stock in a transaction dated Monday, August 10th. The stock was bought at an average price of $16.00 per share, with a total value of $96,000.00. Following the completion of the transaction, the director owned 6,000 shares of the company’s stock, valued at $96,000. This represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders purchased 1,573,900 shares of company stock valued at $25,181,900.

About BlossomHill Therapeutics

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.